The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases.
CEA
cell-free DNA
circulating tumor DNA
colorectal cancer
ctDNA
liquid biopsy
liver metastasis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Aug 2020
27 Aug 2020
Historique:
received:
31
07
2020
revised:
21
08
2020
accepted:
25
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
2
9
2020
Statut:
epublish
Résumé
Colorectal cancer (CRC) belongs to the most common cancers. The liver is a predominant site of CRC dissemination. Novel biomarkers for predicting the survival of CRC patients with liver metastases (CLM) undergoing metastasectomy are needed. We examined KRAS mutated circulating cell-free tumor DNA (ctDNA) in CLM patients as a prognostic biomarker, independently or in combination with carcinoembryonic antigen (CEA). Thereby, a total of 71 CLM were retrospectively analyzed. Seven KRAS G12/G13 mutations was analyzed by a ddPCR™ KRAS G12/G13 Screening Kit on QX200 Droplet Digital PCR System (Bio-Rad Laboratories, Hercules, CA, USA) in liver metastasis tissue and preoperative and postoperative plasma samples. CEA were determined by an ACCESS CEA assay with the UniCel DxI 800 Instrument (Beckman Coulter, Brea, CA, USA). Tissue KRAS positive liver metastases was detected in 33 of 69 patients (47.8%). Preoperative plasma samples were available in 30 patients and 11 (36.7%) were KRAS positive. The agreement between plasma- and tissue-based KRAS mutation status was 75.9% (22 in 29; kappa 0.529). Patients with high compared to low levels of preoperative plasma KRAS fractional abundance (cut-off 3.33%) experienced shorter overall survival (OS 647 vs. 1392 days,
Identifiants
pubmed: 32867151
pii: cancers12092434
doi: 10.3390/cancers12092434
pmc: PMC7565270
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : This work was supported by the grant of Ministry of Health of the Czech Republic - Conceptual Development of Research Organization (Faculty Hospital in Pilsen - FNPl, 00669806), by the Charles University Research Fund (Progres Q39), and by program LTAUSA1
ID : FNPl, 00669806; Progres Q39; LTAUSA19080
Références
BMC Cancer. 2018 Jan 15;18(1):78
pubmed: 29334918
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Surg Oncol. 2009 Mar;18(1):15-24
pubmed: 18619834
EPMA J. 2018 Aug 17;9(3):271-285
pubmed: 30174763
Int J Mol Sci. 2018 Oct 26;19(11):
pubmed: 30373199
Int J Cancer. 2018 Oct 15;143(8):1963-1977
pubmed: 29756328
Anticancer Res. 2005 Jan-Feb;25(1B):657-61
pubmed: 15816642
J Exp Clin Cancer Res. 2014 Dec 10;33:104
pubmed: 25491325
J Clin Oncol. 2016 Jan 10;34(2):179-85
pubmed: 26438111
Int J Surg. 2013;11 Suppl 1:S54-7
pubmed: 24380554
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234350
Int J Cancer. 2002 Aug 10;100(5):542-8
pubmed: 12124803
Br J Cancer. 2018 Dec;119(12):1464-1470
pubmed: 30467411
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
Ann Coloproctol. 2019 Dec;35(6):294-305
pubmed: 31937069
Nat Rev Cancer. 2003 Jun;3(6):459-65
pubmed: 12778136
Clin Cancer Res. 2016 Jun 15;22(12):3067-77
pubmed: 26847055
Br J Cancer. 2011 Mar 15;104(6):1020-6
pubmed: 21364579
J Gastrointest Oncol. 2019 Dec;10(6):1274-1298
pubmed: 31949948
Nat Rev Clin Oncol. 2009 Sep;6(9):519-27
pubmed: 19636327
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
Gastroenterol Res Pract. 2017;2017:9858931
pubmed: 28596788
Br J Haematol. 1994 Apr;86(4):774-9
pubmed: 7918071
Br J Cancer. 2013 Dec 10;109(12):3067-72
pubmed: 24263065
Cancer Manag Res. 2019 Aug 07;11:7499-7511
pubmed: 31496807
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Clin Cancer Res. 2015 Dec 15;21(24):5469-79
pubmed: 26341920
Oncol Lett. 2020 Jul;20(1):742-750
pubmed: 32566000
Int J Biol Markers. 2006 Oct-Dec;21(4):223-8
pubmed: 17177160
Zhonghua Zhong Liu Za Zhi. 2013 Sep;35(9):666-71
pubmed: 24332053
Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71
pubmed: 8118388
Clin Cancer Res. 2000 Jun;6(6):2129-37
pubmed: 10873061
Clin Cancer Res. 2012 Feb 15;18(4):1177-85
pubmed: 22228631
Mol Oncol. 2017 Feb;11(2):208-219
pubmed: 28106345
Mod Pathol. 2013 Jun;26(6):825-34
pubmed: 23348904
Ann Surg Oncol. 2009 Nov;16(11):3087-93
pubmed: 19629600
Int J Cancer. 2020 Jan 15;146(2):566-576
pubmed: 31199507
Gut. 2016 Apr;65(4):625-34
pubmed: 25654990
Oncotarget. 2015 Nov 10;6(35):38360-71
pubmed: 26451609
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
PLoS One. 2015 Apr 13;10(4):e0108247
pubmed: 25875772
Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134
pubmed: 26661580
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Immunol Res. 2018 Oct 14;2018:7169081
pubmed: 30406153
Ann N Y Acad Sci. 2006 Sep;1075:185-90
pubmed: 17108210